Thus, we can propose that inhibition or activation of the protein kinases such as AKT, HIPK2, AMPK, MET, JNK, HIF-1α, and CD44 by treatment with CDPs in the mouse melanoma model could involve the blocking of the substrate binding site as a molecular mechanism. Here, AKT1 is linked to melanoma.